Physician profile
Yaping Wu
NPI 1164504171
$15,677.62
in general payments reported to CMS, 2019-2025
13 companies · $77.83 in 2025
The $77.83 reported for 2025 was more than what a typical Anatomic Pathology & Clinical Pathology provider received nationally (typical 2025 total: $50.59).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $652 · 2020: $7,545 · 2021: $2,060 · 2022: $4,852 · 2023: $346 · 2024: $145 · 2025: $77.83.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $568.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $568.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $4,880.80 | 2022-2023 | |
| Amgen INC. | $3,894.00 | 2020 | |
| Astrazeneca Pharmaceuticals Lp | $3,140.56 | 2020-2022 | |
| Roche Molecular Systems, INC. | $2,555.55 | 2020 | |
| Stemline Therapeutics INC. | $247.12 | 2019-2020 | |
| Roche Diagnostics Corporation | $200.39 | 2019-2023 | Cintec Plus Cytology |
| Merck Sharp & Dohme LLC | $147.45 | 2019-2022 | |
| Adaptive Biotechnologies Corporation | $144.72 | 2024 | Clonoseq |
| Blueprint Medicines Corporation | $123.78 | 2023 | Ayvakit |
| Genentech USA, INC. | $99.60 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $91.96 | 2019 | |
| Sanofi US Services INC. | $77.83 | 2025 | |
| Celgene Corporation | $73.86 | 2023 | Reblozyl |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yaping Wu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.